Morphological predictors for microsatellite instability in urothelial carcinoma

Eduardo Sobrino Reig
Tajo Hospital: Hospital Universitario del Tajo  https://orcid.org/0000-0002-7529-5101

Eduardo Sobrino-Reig
Tajo Hospital: Hospital Universitario del Tajo

Telma Meizoso
Mostoles University Hospital: Hospital Universitario de Mostoles

Jesús García
Mostoles University Hospital: Hospital Universitario de Mostoles

David Varillas-Delgado
Francisco de Vitoria University: Universidad Francisco de Vitoria

Yasmina B. Martin (✉ y.martin.prof@ufv.es)
Francisco de Vitoria University: Universidad Francisco de Vitoria

Research

Keywords: cancer, mismatch repair, immunohistochemistry, screening protocol, tissue microarray

DOI: https://doi.org/10.21203/rs.3.rs-646067/v1

License: ☺️ © This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Introduction

Microsatellite instability occurs due to a series of mutations in the DNA pairing error repair (Mismatch repair; MMR) genes, which can affect germ cells as occurs in Lynch syndrome, whose patients are at high risk of developing multiple cancers. The loss of MMR protein is commonly determined by immunohistochemical studies. Although the relation between microsatellite instability and urothelial carcinomas has been widely studied, its evaluation is not currently performed in the analysis of urothelial carcinomas.

Methods

In this study, the microsatellite status of 139 urothelial carcinomas was analyzed and their clinicopathological characteristics were evaluated. We identified that 10.3% (13 patients) of urothelial carcinomas had loss of MMR protein expression (9 MLH1; 5 MSH2; 2 PMS2; 2 PSH6; n = 139).

Results

Results suggest that these tumors occur more frequently in males, are more frequently located in the bladder or ureters, and present a high tumor grade with a papillary histological pattern that does not infiltrate the lamina propria or, in the case of infiltrating tumors, that grows into perivesical tissues.

Conclusions

We identified patients with the aforementioned tumor characteristics as patients with a high probability of presenting microsatellite instability, and consider that only these patients should undergo further immunohistochemical and molecular techniques for proper diagnosis. Therefore, we propose that the clinicopathological characteristics found in the present study could become possible markers to determine which cases should undergo additional tests.

1. Introduction

Cancer stands as one of the leading public health issues of our times. Currently, one in three women and one in two men will develop a tumor during their lifetime. The increase in cancer prevalence has been related to the aging and growth of the population and improvements in life expectancy (1).

Urothelial carcinoma is the twelfth most common cancer worldwide (2), and the fifth most common cancer in Spain (3). Estimates indicate a global incidence of 573,278 new cases per year, which cause approximately 212,536 annual deaths (2). The incidence of urothelial carcinoma in Spain is estimated in 21,093 people per year (3).
Previous molecular genetic studies have shown a relationship between urothelial carcinomas and microsatellite instability (MSI). Namely, between 1.1% and 28% of urothelial carcinomas present MSI (4–14). MSI is caused by mutations in the genes of the DNA repair system, known as Mismatch repair (MMR) (12), which fail to repair DNA duplication errors. This leads to an accelerated and indiscriminate accumulation of mutations in nucleotides through insertions or deletions (5, 15). Moreover, germline mutations in DNA mismatch repair genes predispose to several gastrointestinal, urologic, gynecologic, and skin tumors at younger ages, also known as Lynch syndrome (7). Carcinogenesis in patients with Lynch syndrome is due to an accumulation of somatic reading frame mutations within microsatellite regions in genes that control growth and apoptosis (4, 5, 12, 15).

The first test to examine the loss of MMR proteins is immunohistochemistry (IHC), which is currently only recommended for colorectal (16–19) and endometrial carcinomas (20–22). This technique is not performed in urothelial carcinomas, although its relationship with MSI has been widely studied (10). In fact, urothelial carcinomas with MSI highly benefit from adjuvant cisplatin-based chemotherapy (23), as well as the use of antibodies against CTLA4 and PD-1 (24). Patients with urothelial carcinomas with identified MSI could also benefit from prophylactic treatment based on the use of Acetylsalicidal acid (25, 26), hormone replacement therapy (27), ibuprofen or calcium supplements (28, 29). The importance of identifying patients with urothelial carcinomas with MSI is becoming more and more evident, as the clinical differences require specific treatments for better prognosis. Therefore, pathologists an increasing more relevant role in the care of these patients (30).

Several authors, such as Ju (10), Joost (5) and Harper (9) and collaborators, have shown a correlation between the clinical and histological characteristics of urothelial carcinomas and the presence of MSI. Urothelial carcinomas with MSI are usually high-grade papillary tumors without the presence of marked nuclear pleomorphism, in stages pTa or pT1, with the presence of intratumoral lymphocytosis (20 lymphocytes per 10 HPF). They occur more frequently in men between 36 and 90 years of age and are mainly located in the bladder, although they can be found in any location lined by urothelial mucosa.

The aim of this study is to identify patients with urothelial carcinomas with presence of MSI. Although it is already known that carrying out an IHC and molecular study would allow the diagnosis of all patients, the economic cost is too high. Therefore, we propose to use the histological characteristics of the tumor and the clinical data of the patient as a guide to classify patients as in “high” or “low risk of presenting MSI” as a first approach to narrow down the number of patients that are submitted to take additional tests. In this sense, only patients classified as “high risk of presenting MSI” would continue with MSI analysis. This system would allow all patients to receive a correct screening for MSI with a single histological section stained with Hematoxylin - eosin (H&E).

2. Materials And Methods

2.1. Study design and case selection
An observational study was carried out by reviewing cases of urothelial carcinoma. Clinical data, histological sections and IHC stains of urothelial tumors from the University Hospital of Móstoles, (Madrid, Spain) were used.

A total of 139 cases with transitional cell carcinoma were selected, which had been diagnosed by the Pathological Anatomy Service of the University Hospital of Móstoles from January 2013 to June 2014. All the data used and obtained were coded and treated anonymously throughout the study. The study was approved by the Research Committee of the University Hospital of Móstoles, (Madrid, Spain) (No. org / int 005/2018).

2.2. Inclusion and exclusion criteria

To avoid bias in the selection of cases, samples from patients with a tumor coded as "transitional cell carcinoma" were included in the study, accepting any location or stage with available material. Transitional cell carcinoma samples smaller than 0.3 cm in size were excluded from the study to avoid consuming the entire sample, which may be necessary for future studies.

2.3. Clinical analysis

Patients were classified according to their gender (male or female), age (in 5 groups: Group 1: 0–49 years; Group 2: 50–59 years; Group 3: 60–69 years; Group 4: 70–79 years Group 5: 80–99 years) and tumor location at the time of diagnosis (bladder, urethra and ureters).

2.4. Pathologic analysis

Tumors were analyzed in blind conditions by a single pathologist. A representative block of urothelial carcinoma was received from the Anatomic Pathology Service of the University Hospital of Móstoles, and sections stained with hematoxylin and eosin-stained (H&E) were prepared. The H&E sections were reviewed, and the following histological criteria were used to evaluate the tumors:

- **Histology of the tumor**

The tumor architecture and the type of cells that constitute the tumor were studied. For this purpose, the current WHO 2017 (31) classification parameters of urothelial tumors were used, assessing the following subtypes:

- Urothelial carcinoma with squamous differentiation.

- Urothelial carcinoma with solid nests.

- Papillary urothelial carcinoma.

- Mixed urothelial carcinoma.

- **Classification of tumor staging**
The classification was conducted according to the “Protocol for the Examination of Specimens From Patients With Carcinoma of the Urinary Bladder” the 8th Edition, AJCC Staging Manual, June 2017 (31) (Table 1).

Table 1
Tumor classification according to the grade of invasion as defined in (31).

| Stage | Definition |
|-------|------------|
| Ta    | Papillary noninvasive carcinoma. |
| Tis   | Flat urothelial carcinoma in situ. |
| T1    | Tumor invades lamina propria.  
*Connective tissue between the urothelium and the detrusor muscle.* |
| T2    | Tumor invades muscularis propria.  
*Thick bundles of detrusor muscle.* |
| T3    | Tumor invades perivesical tissue.  
*Adipose tissue beyond muscularis propria.*  
*T3a: microscopic invasion.*  
*T3b: macroscopic invasion.* |
| T4    | Tumor invades other organs. |

- *Histologic grade*

The tumors received a single grade of differentiation (high or low) according to the criteria included in the “College of American Pathologist” (31).

- *Tumor necrosis or evident apoptosis*

Tumors were evaluated for the presence or absence of necrosis. The tumor was classified as negative if the focus of necrosis was less than 10%. Large geographic areas of necrosis (necrotic tumor) were not included.

Samples were classified into two groups: with or without tumor necrosis or apoptosis.

- *Presence of nucleolus*
The presence or absence of nucleolus in the nuclei was examined. When a nucleolus was identified, it was classified according to its intensity. Samples were classified in three groups defined as follows: G0: nucleolus is not identified or not evident; G+: evident nucleolus is identified at 400x magnification; G++: obvious nucleolus is identified at 200x magnification.

- **Growth pattern**

The growth pattern of the tumor was examined, and two groups were established: “Growth pattern with exophytic characteristics”, for tumors which show an outward growth, that is, towards the bladder or towards the tubular lumens in the case of tumors located at the level of the ureter or urethra; and “growth pattern of endophytic characteristics”, which included tumors that grow towards the chorion.

- **Lymphovascular invasion**

The presence of tumor urothelial cellularity inside lymphatic and blood vessels was examined. They were classified into two groups: a first group for tumors in which there is no evidence of invasion in the lymphatic vessels or blood vessels, and a second group in which lymphovascular invasion can be identified.

- **Perineural invasion**

When studying the nerves, the presence of urothelial carcinoma was observed in different locations, such as within the perineurium, within the nerve, surrounding the nerve or invading ganglionic tissue. Tumors were classified in two groups, according to whether perineural invasion was present or absent.

- **Presence of peritumoral lymphocytes**

The percentage of lymphocyte cellularity in five high-power fields was analyzed in the peritumoral stroma, preferably considering the areas with more lymphocytes (hot-spot). Tumors were classified in three blocks: Block P0: there is no lymphocytic infiltrate, less than 5%. Block P1: evidence of minimal lymphocytic infiltrate, between 5 and 15%. Block P2: presence of evident lymphocytic infiltrate, greater than 15%.

- **Presence of intratumoral lymphocytes**

At the tumor level, the percentage of lymphocyte cellularity in five high-magnification fields of each sample was studied, preferably considering the areas that had more lymphocytes (hot-spot). Apoptotic cells were not counted. Classification was designed in three blocks: Block L0: there is no lymphocytic infiltrate, less than 5%; Block L1: evidence of minimal lymphocytic infiltrate, between 5 and 15%; Block L2: presence of evident lymphocytic infiltrate, greater than 15%.

**2.5. Microsatellite analyses**
Two tissue microarrays were performed on the studied samples, including the most representative parts of the tumor. The construction of the tissue microarrays was carried out in the Histopathology Unit of the Spanish National Cancer Research Center (CNIO), Madrid. A total of 139 tumor tissue samples and 2 control tissue samples (tonsil tissue) were included in each tissue microarray. Sections between 2 and 5 \( \mu \text{m} \) of the tissue microarray blocks were made. Sections were deparaffinized and stained with H&E to verify the correct construction of the blocks and the representation of all cases. Once the blocks were verified, sections between 2 and 5 \( \mu \text{m} \) were made to perform the immunohistochemical (IHC) techniques. The IHC techniques were performed using antibodies against MutL Homolog 1 (MLH1), MutL Homolog 2 (MSH2), MutL Homolog 6 (MSH6), and Postmeiotic Segregation Increased 2 (PMS2). IHC hybridizations analyses were conducted at the Department of Anatomic Pathology of the University Hospital of Móstoles and at CNIO.

2.6. Statistical analysis

Statistical analysis was performed using the SPSS 21.0® package for Windows ((IBM Corp. Released 2012. IBM SPSS Statistics for Windows, Version 21.0. Armonk, NY: IBM Corp). Categorical variables were expressed by frequencies and percentages. Statistical inference was made using the Chi-square test for analysis of nominal variables, Mann-Whitney U test for comparison of ordinal variables and binary logistic regression for predictor variables, carrying out multivariate back-step analysis to define models. Results were considered statistically significant at a p-value < 0.05.

3. Results

3.1. Tumor and patient characteristics from the population sample of Móstoles

The demographic and clinicopathologic data of the 139 patients diagnosed with urothelial carcinoma are shown in Table 2. The average age at diagnosis was between 60 and 70 years. Diagnosis was slightly more frequent in women than men. The most common location of the tumor was found in the bladder (93.5%), followed by the urethra and ureter (4.3% and 2.3%, respectively).

The microscopic study identified that the patients studied from the population of Móstoles presented in most cases a papillary histological pattern (79 patients out of 139), with a predominant exophytic growth of high tumor grade with necrosis and the presence of nucleolus in 46.1% of the cases. These tumors had a low presence of intratumoral lymphocytes and peritumoral lymphocytes. The study of the degree of tumor infiltration showed that in more than half of the cases the urothelial tumors were non-muscle invasive. Vascular invasion was identified in only 1 of the cases and perineural invasion in none of the samples studied.
### Table 2
Patient and tumor characteristics of 139 patients diagnosed with “transitional cell carcinoma”.

| Characteristic                          | % (N)                       |
|-----------------------------------------|-----------------------------|
| **Age**                                 |                             |
| < 49 years                              | 5.7% (8)                    |
| 50–59 years                             | 12.9% (18)                  |
| 60–69 years                             | 39.6% (55)                  |
| 70–79 years                             | 23.74% (33)                 |
| > 80 years                              | 17.98% (25)                 |
| **Sex**                                 |                             |
| Male                                    | 67.6 (94)                   |
| Female                                  | 32.4 (45)                   |
| **Localization**                        |                             |
| Bladder                                 | 93.5% (103)                 |
| Urethra                                 | 4.3% (6)                    |
| Ureter                                  | 2.3% (3)                    |
| **Histology of the tumor**              |                             |
| Papillary                               | 56.83% (79)                 |
| Mixed                                   | 28.05% (39)                 |
| Solid                                   | 12.9% (18)                  |
| Squamous differentiation                | 2.16% (3)                   |
| **Classification of tumor staging**     |                             |
| No infiltration                         | 35.25% (49)                 |
| Infiltration of lamina propia           | 49.6% (69)                  |
| Infiltration of muscle                  | 10.8% (15)                  |
| Infiltration of perivesical tissue      | 3.6% (5)                    |
| Infiltration of other organs            | 0.7% (1)                    |
| **Histologic grade**                    |                             |
| Low                                     | 59.6% (80)                  |
| High                                    | 42.2% (59)                  |
| **Tumor necrosis or evident apoptosis.**|                             |
| Yes                                     | 53.25 (74)                  |
| No                                      | 46.75% (65)                 |
| **Growth pattern**                      |                             |
| Endophytic                              | 14.4% (20)                  |
| Exophytic                               | 85.6% (119)                 |
| **Presence of nucleolus**               |                             |
| No                                      | 53.95% (75)                 |
| Characteristic                      | % (N)    |
|------------------------------------|----------|
| Yes +                              | 22.30% (31) |
| Yes ++                             | 23.74% (33) |
| Lymphovascular invasion            |          |
| Yes                                | 2.2% (3)  |
| No                                 | 97.8% (136) |
| Neural invasion                    |          |
| Yes                                | 0% (0)   |
| No                                 | 100% (139) |
| Presence of peritumoral lymphocytes|          |
| 0–5%                               | 46.76% (65) |
| 6–30%                              | 33.18% (47) |
| >30%                               | 19.42% (27) |
| Presence of intratumoral lymphocytes|        |
| 0–5%                               | 85.61% (119) |
| 6–20%                              | 10.07% (14)  |
| >20%                               | 4.31% (6)   |

### 3.2. MSI Study

After analyzing the characteristics of the tumors and confirming that they present similar characteristics to the general population, we divided tumor samples into two groups. The first group included patients with MSI (no identified immunoreactivity in any of the genes involved in the study) and the other group included patients who did not present alterations at this level. Tumor sample classification resulted in the identification of 13 patients (10.3%) who presented MSI and 126 (89.7%) who did not present MSI (Table 3).
Results from the association analysis between patient/tumor factors and the presence or absence of MSI are shown in Table 4. When assessing the frequency of mutation between patient genders, it was observed that MSI was statistically more frequent in men (22.2%) compared to women (3.2%), showing a risk of MSI in men with an Odd Ratio (OR) of 6,963 (95% CI: 2.014–24.069; p < 0.001).

The age categories did not show statistical differences regarding MSI. No MSI was observed in patients under 49 years of age, whereas the rest of the age categories showed instability percentages between 6.1% and 12.0% (p = 0.795).

The ureters were statistically significantly the most common location in which MSI was present, with 50% of the cases showing MSI in this location (95% CI: 2,137 – 67,380; p = 0.001). The OR risk of presenting MSI in the ureters was 12,000 times the risk of presenting MSI in the bladder or urethra.

Regarding tumor infiltration in the lamina propria, no statistically significant differences (p = 0.141) were observed between MSI and the presence (6.9%) or absence (14.9%) of infiltration.

The study of the degree of tumor infiltration based on the tumor staging guidelines from the “Collage of American Pathologist” (31) showed statistical differences between the risk of presenting MSI between patients with tumors that do not infiltrate the lamina propria (pTa) and those patients with tumors that

| MLH1 | PMS2 | MSH2 | MSH6 |
|------|------|------|------|
| Patient 1 | +    |      |      |
| Patient 2 |      |      |      |
| Patient 3 |      | +    |      |
| Patient 4 |      |      |      |
| Patient 5 |      |      |      |
| Patient 6 |      | +    | +    | +    |
| Patient 7 |      |      |      |
| Patient 8 |      |      |      |
| Patient 9 |      | +    | +    | +    |
| Patient 10 |      |      | +    |
| Patient 11 |      |      |      |
| Patient 12 |      | +    |      | +    |
| Patient 13 |      |      |      | +    |
infiltrate the lamina propria (pT1), with an OR of 9.857 (95% CI: 1.253–77.575; \( p = 0.006 \)). An OR of 102.00 (95% CI: 7.103-1464.69; \( p < 0.001 \)) of presenting MSI was found in patients with tumors that cause infiltration to perivesical tissues (pT3) compared to patients with tumors whose infiltration is limited to the lamina propria (pT1).

The most frequent tumor grade in both groups (presence and absence of MSI) was “high grade”. No statistical differences were observed between presenting a high (8.8%) or low grade (10.2%) within the MSI group (\( p = 0.776 \)). Similarly, no statistical differences were observed within the MSI group between tumor growth with endophytic characteristics (8.4%) and growth with exophytic characteristics (15.0%) (\( p = 0.349 \)).

The rest of the parameters evaluated did not present statistically significant differences between carcinomas with and without MSI (Table 4).
Correlation between the presence or absence of microsatellite instability with parameters of influence in the different tumors.

| Factor                  | Microsatellite instability (MSI) | Si   | No   | P-value |
|-------------------------|---------------------------------|------|------|---------|
| **Age**                 |                                 |      |      |         |
| <49 years               |                                 | 0.0% | 100.0% | N.S.    |
| 50–59 years             |                                 | 11.1% | 88.9% |         |
| 60–69 years             |                                 | 10.9% | 89.1% |         |
| 70–79 years             |                                 | 6.1%  | 93.9% |         |
| >80 years               |                                 | 12.0% | 88.0% |         |
| **Sex**                 |                                 |      |      |         |
| Male                    |                                 | 22.2% | 77.8% | < 0.001 |
| Female                  |                                 | 3.2%  | 96.8% |         |
| **Localization**        |                                 |      |      |         |
| Bladder                 |                                 | 7.7%  | 92.3% | 0.001   |
| Urethra                 |                                 | 0.0%  | 100.0% |         |
| Ureter                  |                                 | 50%   | 50%   |         |
| **Histology of the tumor** |                               |      |      |         |
| Papillary               |                                 | 11.5% | 88.5% | N.S.    |
| Mixed                   |                                 | 5.3%  | 94.7% |         |
| Solid                   |                                 | 11.8% | 88.2% |         |
| Squamous differentiation |                                 | 0.0%  | 100.0% |         |
| **Classification of tumor staging** |                       |      |      |         |
| No infiltration         |                                 | 14.3% | 85.7% | 0.006 (LP) |
| Infiltration of lamina propia |                         | 1.4%  | 98.6% | < 0.001 (TP) |
| Infiltration of muscle  |                                 | 13.3% | 86.7% | N.S.    |
| Infiltration of perivesical tissue |                     | 40.0% | 60.0% | N.S.    |
| Infiltration of other organs |                             | 0.0%  | 100.0% | N.S.    |
| **Histologic grade**   |                                 |      |      |         |
| Low                     |                                 | 10.2% | 89.8% | N.S.    |
| High                    |                                 | 8.8%  | 91.2% |         |

N.S. = no statistical significance
|                                | Microsatellite instability (MSI) |
|--------------------------------|----------------------------------|
| **Tumor necrosis or evident apoptosis.** |                                 |
| Yes                            | 5.4% 94.6% 0.088                |
| No                             | 13.8% 86.2%                     |
| **Growth pattern**             |                                 |
| Endophytic                     | 8.4% 91.6% N.S.                 |
| Exophytic                      | 15.0% 85.0%                     |
| **Presence of nucleolus**      |                                 |
| No                             | 13.3% 86.7% N.S.                |
| Yes +                          | 6.5% 93.5%                      |
| Yes ++                         | 3.0% 97.0%                      |
| **Lymphovascular invasion**    |                                 |
| Yes                            | 33.3% 66.7% N.S.                |
| No                             | 8.8% 91.2%                      |
| **Neural invasion**            |                                 |
| Yes                            | 9.4% 90.6% N.S.                 |
| No                             | 9.4% 90.6%                      |
| **Presence of peritumoral lymphocytes** |     |
| 0–5%                           | 55.30% 44.40% N.S.              |
| 6–30%                          | 39.10% 35.70%                   |
| > 30%                          | 12.80% 19.80%                   |
| **Presence of intratumoral lymphocytes** |                     |
| 0–5%                           | 92.30% 84.90% N.S.              |
| 6–20%                          | 0.00% 11.10%                    |
| > 20%                          | 7.70% 4.00%                     |

N.S. = no statistical significance

### 4. Discussion

The histopathological identification of different phenotypic characteristics is correlated with a molecular classification, which is how classical surgical pathology can be linked with newer molecular analysis techniques (32, 33). In our study, we demonstrated that urothelial carcinomas with potential MSI can be identified by evaluating histopathological and clinical data of the patients.

The analysis of the clinical and histological characteristics of our tumors and their comparison with the general population (4, 8, 34, 35), suggested that our series is representative of urothelial carcinomas. This is because the variables studied presented the usual trends of urothelial tumors found in the general population.
Our research showed that 10.3% of urothelial carcinomas presented MSI, which were identified using IHC. Results showed that MSI most frequently occurs due to mutations in MLH1, followed by MSH2, PMS2 and MSH6. These results are in accordance with previous studies (5, 9–11, 36).

In our study sample, patients that presented urothelial carcinoma with MSI, identified by IHC, apparently sporadic, were more frequently men and tumors were located in most cases at the level of the ureters and bladder. The histological study showed that these neoplastic proliferations presented a papillary pattern of high tumor grade that in most cases did not infiltrate the lamina propria or, in the case of infiltrating tumors, produced an infiltration into perivesical tissues.

Previous studies by Joost (5), Harper (9) and Ju (10) validate and expand our findings. These authors observed that patients with potential MSI have several characteristics in common. They are usually high-grade papillary tumors without the presence of marked nuclear pleomorphism in stages pTa or pT1, although they can be found in any tumor stage (5, 9, 10). They are tumors that occur mainly in the ureters and bladder, although they can be found in any location lined by urothelial mucosa (5, 10). Regarding the age of diagnosis, tumors with MSI occur more frequently in patients between 36 and 90 years old. This is in line with the results from our study, in which more than 61.5% of our patients presented tumors in stages pTa or pT1. The next most frequent tumor stage was pT3, which could be due to a late diagnosis of our patients, which led to a more advanced tumor stage. In relation to the presence of intratumoral lymphocytosis, our results differed from the study by Ju et al. (10). The authors observed 20 lymphocytes per 10 HPF, whereas in our study very few patients presented intratumoral lymphocytes. This difference may be due to the design of the study, since we assessed intratumoral lymphocytosis in a hot-spot field, whereas Ju and collaborators counted the number of lymphocytes in 10 HPF. This difference in the design limits the comparison of results from the different studies.

On the other hand, we found differences in our results compared to previous studies. Urakami et al. (11) observed that tumors with MSI were more frequent in women, presented an inverted papillary pattern of low cytological grade and were diagnosed more frequently at pTa or pT1 stages. Our results differ at the gender, tumor pattern and grade levels. These differences may be due to the diversity of the population sample used, as Urakami et al. conducted their research in Tokyo, Japan. Dissimilarities between the European and Asian populations have been previously reported in other tumors, such as the squamous cell carcinoma of the lung, whose incidence in Europe is more frequent in men, whereas in Asia it occurs more frequently in women (37).

Our study highlights that the identification of MSI in urothelial carcinomas using a combination of histology data together with the clinical data of patients may provide an early detection tool for patient classification, and thus, a rapid tool for screening. It is also evidenced that evaluating histopathological and clinical data independently are not reliable enough to discriminate those patients with a higher probability of presenting MSI. In this sense, we propose a protocol which integrates both data for patient classification (Fig. 1).
According to this protocol, once the patients with the highest probability of presenting MSI have been identified, they should undergo immunohistochemical techniques for MSI evaluation. This screening reduces the number of requests for IHC techniques, since IHC will only be performed on those patients with clinical suspicion or those who meet the aforementioned histological and clinical characteristics. If patients do not express any of the IHC markers, a molecular study would be carried out. The advantages of using this screening system could include an early detection of patients with MSI, a reduction of economic costs as fewer IHC tests would be conducted, and, in the long term, a reduction of the morbidity and mortality of patients.

5. Conclusion

There is wide evidence that urothelial carcinomas present MSI. In our study, the prevalence of urothelial carcinomas with MSI was 10.3%. The combination of clinical data and histopathological characteristics may allow early identification of patients with high risk of presenting MSI. Our study identified that these patients as male, with a tumor located in the bladder or ureters at the time of diagnosis, with a papillary histological pattern that does not infiltrate the lamina propria or, in the case of infiltrating tumors, that infiltrates perivesical tissues. We propose the evaluation of the clinicopathological characteristics identified in the present study to be applied as a screening guide, to help practitioners decide which cases should undergo additional tests. This protocol is prosed as a cost-effective tool that may help early diagnosis of patients with MSI, reducing morbidity and mortality without implying an increase in work for the pathologist and laboratory technicians.

Abbreviations

MMR
Mismatch repair
MSI
Microsatellite instability
IHC
Immunohistochemistry
HPF
High-power field
H&E
Hematoxylin - eosin
MLH1
MutL Homolog 1
MSH2
MutL Homolog 2
MSH6
MutL Homolog 6
Declarations

Acknowledgments

The authors would like to thank the Pathological Anatomy Department of the University Hospital of Móstoles and the Spanish National Cancer Research Center for their assistance.

Conflict of interest

The authors declare that they have no conflict of interest.

Funding

None.

Availability of data and materials

Not applicable.

Contributions

ES wrote the manuscript. TM and YM reviewed the case. DV, JG, TM, YM and ES

DV, JG, TM, YM, and ES conducted the pathology study, contributed to the diagnosis, and provided helpful comments. All authors have read and approved the final version of the manuscript.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

References

1. Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012.
2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

3. Galceran J, Ameijide A, Carulla M, Mateos A, Quirós JR, Rojas D, et al. Cancer incidence in Spain, 2015. Clin Transl Oncol. 2017.

4. Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part A: Renal, Penile, and Testicular Tumours. Eur Urol. 2016.

5. Joost P, Therkildsen C, Dominguez-Valentin M, Jönsson M, Nilbert M. Urinary Tract Cancer in Lynch Syndrome; Increased Risk in Carriers of MSH2 Mutations. Urology. 2015.

6. Eriksson P, Therkildsen C, Höglund M, Jönsson M, Sjödahl G, Nilbert M, et al. Molecular subtype classification of urothelial carcinoma in Lynch syndrome. Eur Urol Suppl. 2018.

7. Pradere B, Lotan Y, Roupret M. Lynch syndrome in upper tract urothelial carcinoma: Significance, screening, and surveillance. Current Opinion in Urology. 2017.

8. Metcalfe MJ, Petros FG, Rao P, Mork ME, Xiao L, Broaddus RR, et al. Universal Point of Care Testing for Lynch Syndrome in Patients with Upper Tract Urothelial Carcinoma. J Urol. 2018.

9. Harper HL, McKenney JK, Heald B, Stephenson A, Campbell SC, Plesec T, et al. Upper tract urothelial carcinomas: Frequency of association with mismatch repair protein loss and Lynch syndrome. Mod Pathol. 2017.

10. Ju JY, Mills AM, Mahadevan MS, Fan J, Culp SH, Thomas MH, et al. Universal Lynch Syndrome Screening Should be Performed in All Upper Tract Urothelial Carcinomas. Am J Surg Pathol. 2018.

11. Urakami S, Inoshita N, Oka S, Miyama Y, Nomura S, Arai M, et al. Clinicopathological characteristics of patients with upper urinary tract urothelial cancer with loss of immunohistochemical expression of the DNA mismatch repair proteins in universal screening. Int J Urol. 2018.

12. Morales Cristina PMA. Inestabilidad de microsatélites: papel diagnóstico e implicaciones pronósticas. GH Contin. 2006;5.

13. Lindner AK, Schachtner G, Tulchiner G, Thurnher M, Untergasser G, Obrist P, et al. Lynch syndrome: Its impact on urothelial carcinoma. Int J Mol Sci. 2021;22(2):1–21.

14. Fraune C, Simon R, Hube-Magg C, Makrypidi-Fraune G, Kähler C, Kluth M, et al. MMR deficiency in urothelial carcinoma of the bladder presents with temporal and spatial homogeneity throughout the tumor mass. Urol Oncol Semin Orig Investig. 2020;38(5):488–95.

15. Roa SJC, Araya OJC, Villaseca HMA, Roa EI, Correa P. Inestabilidad microsatelital y pérdida de la heterocigocid en lesiones neoplásicas y preneoplásicas gástricas. Rev Med Chil. 2003.

16. Kawakami H, Zaanan A, Sinicrope FA. HHS Public Access. 2016;16(7):1–14.

17. Chintalacheruvu LM, Shaw T, Buddam A, Diab O, Kassim T, Mukherjee S, et al. Major hereditary gastrointestinal cancer syndromes: A narrative review. Journal of Gastrointestinal and Liver Diseases. 2017.
18. Buza N, Ziai J, Hui P. Mismatch repair deficiency testing in clinical practice. Expert Review of Molecular Diagnostics. 2016.

19. Chen W, Swanson BJ, Frankel WL. Molecular genetics of microsatellite-unstable colorectal cancer for pathologists. Diagn Pathol [Internet]. 2017;12(1):24. Available from: https://doi.org/10.1186/s13000-017-0613-8.

20. Modica I, Soslow RA, Black D, Tornos C, Kauff N, Shia J. Utility of Immunohistochemistry in Predicting Microsatellite Instability in Endometrial Carcinoma. 2007;31(5):744–51.

21. Hashmi AA, Mudassir G, Hashmi RN, Irfan M, Asif H, Khan EY, et al. Microsatellite Instability in Endometrial Carcinoma by Immunohistochemistry, Association with Clinical and Histopathologic Parameters. Asian Pac J Cancer Prev. 2019 Sep;20(9):2601–6.

22. Clarke BA, Cooper K, Path FRC. Identifying Lynch Syndrome in Patients With Endometrial Carcinoma: Shortcomings of Morphologic and Clinical Schemas. 2007;31(5):744–51.

23. Laguna MP. Re. Hereditary-like urothelial carcinomas of the upper urinary tract benefit more from adjuvant cisplatin-based chemotherapy after radical nephroureterectomy than do sporadic tumours. The Journal of urology. 2015.

24. Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz HJ, Morse MA, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017.

25. Burn J, Bishop DT, Mecklin JP, Macrae F, Möselin G, Olschwang S, et al. Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N Engl J Med. 2008.

26. Movahedi M, Bishop DT, Macrae F, Mecklin JP, Moeslein G, Olschwang S, et al. Obesity, aspirin, and risk of colorectal cancer in carriers of hereditary colorectal cancer: A prospective investigation in the CAPP2 study. J Clin Oncol. 2015.

27. Dashti SG, Chau R, Ouakrim DA, Buchanan DD, Clendenning M, Young JP, et al. Female hormonal factors and the risk of endometrial cancer in Lynch syndrome. JAMA - J Am Med Assoc. 2015.

28. Chau R, Dashti SG, Ouakrim DA, Buchanan DD, Clendenning M, Rosty C, et al. Multivitamin, calcium and folic acid supplements and the risk of colorectal cancer in Lynch syndrome. Int J Epidemiol. 2016.

29. Ait Ouakrim D, Dashti S Ghazale, Chau R, Buchanan DD, Clendenning M, Rosty C, et al. Aspirin, Ibuprofen, and the Risk of Colorectal Cancer in Lynch Syndrome. J Natl Cancer Inst. 2015.

30. Shia J, Holck S, Depetris G, Greenson JK, Klimstra DS. Lynch syndrome-associated neoplasms: A discussion on histopathology and immunohistochemistry. Fam Cancer. 2013.

31. AJCC Cancer Staging Manual. AJCC Cancer Staging Manual. 2017.

32. Jass JR. Towards a molecular classification of colorectal cancer. Int J Colorectal Dis. 1999.

33. Weinstein JN, Akbani R, Broom BM, Wang W, Verhaak RGW, McConkey D, et al. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014.

34. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012.
35. Iarc. IA for R on CWHO. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. Globocan. 2012.

36. Catto JWF, Azzouzi AR, Amira N, Rehman I, Feeley KM, Cross SS, et al. Distinct patterns of microsatellite instability are seen in tumours of the urinary tract. Oncogene. 2003.

37. Cheng TYD, Cramb SM, Baade PD, Youlden DR, Nwogu C, Reid ME. The international epidemiology of lung cancer: Latest trends, disparities, and tumor characteristics. J Thorac Oncol. 2016.

Figures
Figure 1

Screening protocol for the identification of patients with urothelial carcinomas with MSI. MSI = microsatellite instability